Natco launches Xtane

Natco Pharma Ltd has announced the launch of Exemestane — a niche product used in the treatment of breast cancer — under the brand name Xtane.

Available as 25 mg. tablets, Exemestane is used in the treatment of breast cancer of post-menopausal women who respond to hormonal therapy and are Hormone Receptor positive. Being the first generic launch of Exemestane, Xtane is priced at around 1/6th of the price of the innovator's brand, in line with the pricing policy of NATCO.

Exemestane would offer a stable and economic option to Hormone Receptor positive patients who are expected to take this medicine for a minimum period of two years.